Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Recruiting now · Phase 2

Conditions studied: Sepsis, Severe

In brief

Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care. This may contribute to the improvement of the impaired organ function of septic shock patients by assisting the impaired immune system (immune competence enhancement = ARTICE)

Key facts

Study ID
NCT05442710
Run by
Artcline GmbH
People needed
142
Starts
2022-07-24
Expected to finish
2026-06-30
Last updated by the study team
2025-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.